Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) PT at $11.17

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been assigned an average rating of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $11.17.

Several research analysts have issued reports on CMPX shares. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. D. Boral Capital reissued a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Jefferies Financial Group lifted their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $5.00 to $4.00 in a research report on Friday, November 15th.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd boosted its position in shares of Compass Therapeutics by 160.9% in the 4th quarter. XTX Topco Ltd now owns 52,754 shares of the company’s stock worth $76,000 after buying an additional 32,533 shares in the last quarter. Mariner LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $30,000. Barclays PLC lifted its holdings in shares of Compass Therapeutics by 13.2% in the fourth quarter. Barclays PLC now owns 192,766 shares of the company’s stock valued at $279,000 after purchasing an additional 22,521 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Compass Therapeutics by 25.2% in the fourth quarter. Renaissance Technologies LLC now owns 278,600 shares of the company’s stock valued at $404,000 after purchasing an additional 56,000 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Compass Therapeutics by 11.3% in the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock valued at $57,000 after purchasing an additional 4,018 shares in the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Stock Down 8.0 %

Shares of NASDAQ CMPX opened at $3.45 on Tuesday. The stock has a market cap of $474.68 million, a PE ratio of -9.32 and a beta of 1.17. Compass Therapeutics has a 52-week low of $0.76 and a 52-week high of $4.08. The business has a 50-day moving average price of $2.24 and a 200 day moving average price of $1.78.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Sell-side analysts anticipate that Compass Therapeutics will post -0.35 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.